[Effects of 2% ibopamine eye drops on the results of computerized visual field].
OBJECTIVE
To evaluate the influence of 2% ibopamine eye drops on the results of computerized visual field exams.


METHODS
Normal volunteers from CEROF-UFG were selected, with no variance in the ophthalmologic examination that could affect the visual field test. The volunteers underwent computerized visual field test before and after dilation with 2% ibopamine eye drop or cyclopentolate, with a minimum interval of three days between them and in a random order. Global indices and number of altered points were compared between the groups.


RESULTS
Thirty eyes of 30 normal individuals were selected. There was no statistically significant difference on Mean Deviation (MD) before and after dilation with ibopamine (MD: -1.05 +/- 0.26 dB vs. -1.47 +/- 0.20 dB, P=0.08). However, after cycloplegia (MD: -3.19 +/- 0.29 dB), there was a significant difference on MD (P<0.001 for both ibopamine and pre-dilation). No significant difference was detected in the Pattern Standard Deviation when comparing ibopamine with pre-dilation and cycloplegia values, but it was statistically significant comparing pre-dilation to cycloplegia (P=0.04). The number of altered points in the Pattern Deviation graphic were not significant comparing all pairs. There was a statistically significant difference in the number of altered points in the total deviation graphic before dilation and after cycloplegia (n: 8.86 +/- 1.51 vs. 25.72 +/- 2.96 points, P<0.001), and comparing cycloplegia with ibopamine (ibopamine: 9.75 +/- 1.85 points, P<0.001).


CONCLUSIONS
Ibopamine 2% eye drops seem to not modify the results of visual field tests in normal individuals.
Pigini
Mara Agi
MA
Universidade Federal de Goiás, Goiânia, GO, Brasil. maraagi@hotmail.com
Avila
Marcos Pereira
MP
Magacho
Leopoldo
L
D000328:Adult; D003519:Cyclopentolate / Q000008:administration & dosage; D003627:Data Interpretation, Statistical; D003846:Deoxyepinephrine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D007091:Image Processing, Computer-Assisted; D008297:Male; D009184:Mydriatics / Q000008:administration & dosage*; D009883:Ophthalmic Solutions / Q000008:administration & dosage; D013997:Time Factors; D058609:Visual Field Tests / Q000379:methods*; D014794:Visual Fields / Q000187:drug effects*
D009184:Mydriatics; D009883:Ophthalmic Solutions; C023487:ibopamine; D003519:Cyclopentolate; D003846:Deoxyepinephrine